Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

Jonathan Allen Webster, MD, Raoul Tibes, MD PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD PhD, Judith E Karp, MD, B. Douglas Smith, MD

Blood (2015) 126 (23): 2563.

https://doi.org/10.1182/blood.V126.23.2563.2563

Published: 2015

Journal Articles

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

Mitch Raponi, PhD, Tatiana Vener, PhD, Carlo Derecho, MSc, Jacqueline Greer, RN, BSN, Sami Malek, MD, John Palma, PhD, Judith E Karp, MD

Blood (2009) 114 (22): 4154.

https://doi.org/10.1182/blood.V114.22.4154.4154

Published: 2009

Journal Articles

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Michael W Evans, MD, MPH, Anthony Sung, MD, Ivana Gojo, MD, Michael L Tidwell, RN, CRNP, Jacqueline Greer, RN, BSN, Mark Levis, Judith Karp, Maria R Baer, MD

Blood (2009) 114 (22): 4126.

https://doi.org/10.1182/blood.V114.22.4126.4126

Published: 2009

Journal Articles

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Judith E. Karp, MD, Rebecca M. Ricklis, MBA, Jacqueline Greer, RN, Janet Briel, RN, Mark J. Levis, MD,PhD

Blood (2006) 108 (11): 1963.

https://doi.org/10.1182/blood.V108.11.1963.1963

Published: 2006

Journal Articles

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Judith E. Karp, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Jacqueline Greer, RN, Valerie Ironside, RN, B. Douglas Smith, MD, Ellen Ritchie, MD, Steven D. Gore, MD, Mark J. Levis, MD,PhD, Scott H. Kaufmann, MD,PhD, Sami Malek, MD, John J. Wright, MD,PhD

Blood (2006) 108 (11): 426.

https://doi.org/10.1182/blood.V108.11.426.426

Published: 2006

Journal Articles

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Jeffrey E. Lancet, MD, Jason Gotlib, MD, Ivana Gojo, MD, Eric J. Feldman, MD, Lawrence Morris, MD, Alain Thibault, MD, Jane L. Liesveld, MD, Jacqueline Greer, RN, Kathleen Dugan, RN, Mitch Raponi, PhD, John J. Wright, MD, PhD, Peter L. Greenberg, MD, Judith E. Karp, MD

Blood (2004) 104 (11): 874.

https://doi.org/10.1182/blood.V104.11.874.874

Published: 2004

NARROW

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Email alerts

ASH Publications

American Society of Hematology

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia

RASGRP1:APTX Gene Expression Ratio Enriches for Responders to the Combination of Tipifarnib and Etoposide in Elderly Newly Diagnosed AML.

Human Immunodeficiency Virus (HIV)-Associated Acute Myeloid Leukemia (AML) in the Era of Highly Active Antiretroviral Therapy (HAART): High Complete Remission Rate, but Poor Tolerance of Consolidation Therapy and Short Disease-Free Survival.

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage.

Active Oral Regimen for Elderly Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML): Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults ≥Age 70 Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC).

Tipifarnib (ZARNESTRA TM in Previously Untreated Poor-Risk AML of the Elderly: Updated Results of a Multicenter Phase 2 Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only